Bill Doyle is the executive chairman of Novocure, an oncology company developing a novel cancer treatment using a proprietary therapy called TTFields, which uses electric fields to disrupt solid tumor cancer cell division. He is also executive chairman of Blink Health, a digital savings platform tackling the high cost of prescription medications.

Previously, Bill served as an executive at Johnson & Johnson, where he served on the consumer pharmaceuticals and medical devices group committees, and as the vice president of Licensing and Acquisitions. Earlier in his career, Bill provided consultation insights at McKinsey & Company. He received his bachelor’s degree in materials science and engineering from the Massachusetts Institute of Technology and an M.B.A. from Harvard Business School.

Speaking of his third- and second-generation Irish heritage, he says his father’s side dates a little farther back than his mother’s. “The first to come to America was Owen Doyle, who emigrated from County Carlow in about 1843 and arrived in Nova Scotia.” Bill’s maternal grandparents were both originally from Belfast. After emigrating, they met by chance in Boston and were married in 1898, where the family has remained ever since.